NCT06423716 Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)
| NCT ID | NCT06423716 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Sunnybrook Health Sciences Centre |
| Condition | Knee Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 150 participants in total. It began in 2024-11-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Knee replacement surgery for osteoarthritis is a commonly performed procedure in Canada with 75,000 of these surgeries performed each year. Success rate for knee replacement surgery is high but more than 20% of patients are still dissatisfied mainly due to reports of ongoing pain. Pain control following knee surgery is important in order to allow patients to engage in recovery and rehabilitation. The current standard of pain management after surgery centers around the use of opioids which is a concerning practice as highlighted by the opioid epidemic. Duloxetine is an antidepressant that has pain relieving properties and it has been studied in patients undergoing knee replacement surgery. Studies to date have not been designed optimally to demonstrate the full effects of opioid dose reduction and the use of duloxetine as a medication following knee replacement surgery. This research study seeks to start duloxetine before surgery, at the recommended therapeutic dose, and for the duration of the early rehabilitation period. If the study is successful, this low-cost medication can improve satisfaction rates and change the standard way the pain management is typically carried out for patients undergoing the knee replacement surgery.
Eligibility Criteria
Inclusion Criteria: 1. Age \>=50 2. Presence of knee osteoarthritis 3. Planned for elective unilateral total knee arthroplasty 4. ASA I - III 5. Baseline creatinine clearance (CrCl) ≥ 30 mL/min within 60 days prior to enrolment, if available. If not available, verbal report from patient of no known renal disease. Exclusion Criteria: 1. Lack of patient consent; unlikely to comply with follow-up 2. Presence of contraindications to study drug use: * Known hypersensitivity to the drug or components of the product * Known liver disease - history of cirrhosis, non-alcoholic steatohepatitis * Uncontrolled narrow - angle glaucoma * Severe renal impairment (CrCl\<30mL/min) * Concurrent use of thioridazine * Concurrent use of potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin) * Concurrent use of antidepressants (e.g. MAOI, SSRI, SNRI, TCA, St. John's Wort, buspirone) * Concurrent use of triptan or lithium 3. Chronic and high dose opioid use (\>30mg oral morphine equivalent per day) 4. Substance use disorder (cannabis and related products, alcohol use disorder, opioid used disorder, illicit drugs) 5. Uncontrolled hypertension (systolic BP \> 180mmHg) 6. Untreated psychiatric illness (e.g. depression, suicidal ideation, bipolar disorder) 7. Involved in worker's compensation case/law suit (verbally declared by patient)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06423716 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06423716 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06423716 currently recruiting?
Yes, NCT06423716 is actively recruiting participants. Contact the research team at howard.meng@sunnybrook.ca for enrollment information.
Where is the NCT06423716 trial being conducted?
This trial is being conducted at Toronto, Canada, Toronto, Canada.
Who is sponsoring the NCT06423716 clinical trial?
NCT06423716 is sponsored by Sunnybrook Health Sciences Centre. The trial plans to enroll 150 participants.